Complement Therapeutics
Clinical trials sponsored by Complement Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study tracks eye disease progression in older adults Results expected Mar 2027 (estimated)
-
Gene therapy injection aims to halt vision loss in AMD patients
Disease control Recruiting nowThis study tests a single injection of CTx001 gene therapy into the eye for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. The trial involves 75 participants and will monitor safety and whether the treatment can slow d…
Phase 1/2 • Sponsor: Complement Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New study tracks eye disease progression in older adults
Knowledge-focused Recruiting nowThis study observes 75 adults aged 55 and older with geographic atrophy (a late stage of age-related macular degeneration) to see how the condition progresses over a short time. Researchers will measure changes in eye structure and function, and explore links to genetics and life…
Sponsor: Complement Therapeutics • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC